Page 416 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C3.2. KQ3 multivariable analyses (continued)
Author Factors Data source Duration Analyzed Population WW/AS Methods Results as described in paper
yr sample characteristics definitions
PMI
Latini 170 Clinical CaPSURE 1989- 5643 Biopsy- Not Multinomial No differences between Latino and
2006 2004 confirmed explicitly logistic non-Latino white men in primary
16400651 prostate cancer provided regression treatment after adjusting for other
patients. RP vs. BT vs. variables (clinical risk, age,
Analysis of EBRT vs. education, marital status, type of
treatment ADT vs. WW insurance, comorbidities, dx yr,
choice was and study site; P-value or
limited to men estimates not reported). No other
with localized information reported for the
disease (clinical association of ethnicity with WW
stage T1 to as compared to other treatments.
T3a).
Marr 165 Clinical CaPSURE 1995- 5149 Men with Not Multinomial 1. Heart disease vs. none OR=3.0
2006 2003 localized explicitly logistic (2.2, 4.2)
16515991 prostate cancer provided regression 2. Stroke vs. none OR=1.2 (0.7,
(T3a or less predicting 2.2)
with no WW vs. RP 3. Urinary conditions vs. none
evidence of OR=1.4 (1.0, 2.1)
lymph or distant 4. comorbidities:
metastases) 1-2 other comorbidities vs. none
OR=1.0 (0.7, 1.6)
3 other comorbidities vs. none
OR=1.6 (0.9, 2.7)
6 or more other comorbidities
vs. none OR=5.2 (1.8, 15.1)
(results were not reported for
other comorbidity groups)
Estimates were adjusted for study
site, dx yr, clinical risk, age,
education, relationship status and
BMI. Regression estimates or p-
values were not provided for these
variables.

C-126